Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of AP-472 conducted in healthy young, middle-aged, and elderly adults

Next Previous
X
Search
Trial Profile

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of AP-472 conducted in healthy young, middle-aged, and elderly adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP-472 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Oct 2021 New trial record
    • 04 Oct 2021 According to an Appello Pharmaceuticals media release, first patient has been enrolled in this study. The study is enrolling subjects at Worldwide Clinical Trials in San Antonio, Texas. Findings from this study will be use for the dose selection of Phase 1b and Phase 2 clinical studies in people with Parkinson's disease.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top